May Health Raises $25M in Series B Funding

may health

May Health, a Paris, France-based clinical-stage medical device company, raised $25M in Series B funding.

The round was led by Bpifrance and Trill Impact with participation from founding investor Sofinnova Partners, as well as Avestria Ventures and Kidron Capital Assets LP. In conjunction with the financing, Nina Rawal, co-head and partner at Trill Impact Ventures Advisory, and Jean-Francois Morin, investment director at Bpifrance, will join May Health’s Board of Directors.

The company intends to use the funds to support its growth and advance its Ovarian Rebalancing™ therapy through the pivotal REBALANCE Study, evaluating its potential to address PCOS-related infertility.

Led by CEO Anne Morrissey, May Health is a clinical-stage medical device company committed to developing treatment options for women living with PCOS. It is currently investigating its Ovarian Rebalancing™ treatment in clinical studies, which is a novel approach to PCOS-related fertility that has the potential to be a safe, straightforward option for activating natural ovulation.

Commenting on the news, Anne Morrissey said: “We are thankful to Bpifrance and Trill Impact for co-leading this financing round, together with our founding investor Sofinnova Partners, and to our deep bench of supporters and advisors for their confidence in our team and growth strategy. We are eager to continue building on the positive results of our previous clinical studies as well as this financing milestone as we work to become a leader in global women’s health and PCOS-related infertility.”